Der zunehmende Einsatz moderner zielgerichteter Therapien führt dazu, dass
Dermatologen stetig mit neuartigen kutanen Nebenwirkungen dieser Substanzen …

Given the increasing use of novel targeted therapies, dermatologists are constantly
confronted with novel cutaneous side effects of these agents. A rapid diagnosis and …

Zusammenfassung Hintergrund Unerwünschte Arzneimittelwirkungen (UAW) sind eine
häufige Fragestellung in der klinischen Praxis. Sie können sich klinisch sehr unterschiedlich …

Moderne Immuntherapeutika wie Nivolumab, Pembrolizumab oder Ipilimumab, die
sogenannte Immun-Checkpoints blockieren, haben die onkologische Therapie in den …

Moderne Immuntherapeutika wie Nivolumab, Pembrolizumab oder Ipilimumab, die
sogenannte Immun-Checkpoints blockieren, haben die onkologische Therapie in den …

Among dermatologic adverse events induced by immune checkpoint inhibitors (ICI), drug
reactions with eosinophilia and systemic symptoms (DRESS) have been very rarely …

Immune checkpoint inhibitors are a new class of oncologic drugs that act via the inhibition of
checkpoints, thereby unlocking the immune system to attack cancer cells. Their emergence …

Introduction Novel anti-cancer drugs such as targeted cancer therapies and immune check-
point inhibitors (ICIs) have adverse events, especially concerning the skin. The aim of this …

Abstract Purpose of Review Immune checkpoint inhibitors (ICIs) have become a mainstay of
oncologic treatment over the past decade. There are currently 11 ICIs approved by the US …

As treatment with immune checkpoint inhibitors (CPIs) for cancer increases, so has the
incidence of immune-related cutaneous adverse events (irCAEs). These toxicities can …